The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that strengthens AbbVie's position in the psoriasis treatment market, its drug Skyrizi has received regulatory approval for treating psoriatic disease in pediatric patients, according to media reports. This new indication expands the potential patient base for the drug, which could boost sales and support revenue growth.
At the stock level, AbbVie shares closed at $243.14 on June 25, 2026, with a daily trading range of $233.66 to $244.61. The approval is seen as a positive step that may enhance investor confidence in the company's growth prospects, especially amid ongoing competition in the biologic therapies market.
Sign in to access this content
Sign InFollowing this development, investors are watching AbbVie's upcoming quarterly results to gauge the impact of the approval on revenues. Resistance at $244.61 remains a near-term target for the stock, while any additional regulatory updates will be closely monitored.